Safety profile of camrelizumab: An analysis based on literature and database review

Yi Huang, Wei Li, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq · 2026

Read Safety profile of camrelizumab: An analysis based on literature and database review by Yi Huang, Wei Li, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13395421.txt.

Description

Yi Huang, Wei Li, and Mohammed Misbah Ul Haq catalogue, in 2026, harms linked to camrelizumab, a cancer immune drug. Reports came from a world safety database covering 2019 to 2025, plus published case reports. Six hundred and one database reports were logged, almost all from Asian patients and mostly men. Eighty case patients from China added detail.

Blood and skin harms led the list, from marrow suppression to rash and a drug-typical growth of tiny skin vessels. Grave events included heart muscle swelling and a blistering skin emergency. Harms struck at a median of eight weeks but could arrive far later. The authors urge early spotting and steroid care for immune harms.

Catalog record

CREATORYi Huang, Wei Li, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq, Mohammed Misbah Ul Haq
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE84992
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13395421

Browse the full library · About the Tower of Babel